FIELD: medicine.
SUBSTANCE: present invention relates to medicine and chemical-pharmaceutical industry, namely to a new pharmaceutical composition containing 5'-O-(3-phenylpropionyl)-N4-hydroxycytidine for treating and/or preventing viral infections, which is a tablet, and containing 5'-O-(3-phenylpropionyl)-N4-hydroxycytidine in amount of 70-80% by weight of composition, disintegrant in amount of 2-6% of the weight of the composition, glidant in an amount of up to 1% of the weight of the composition, a binder in amount of 3-7% of the weight of the composition, lubricant in an amount of up to 1% of the weight of the composition, a filler in an amount of up to 15% of the weight of the composition.
EFFECT: invention provides a high level of solubility, as well as an increase in the biological availability of the API SN9, which in turn makes it possible to increase the effectiveness of the therapy using said drug substance.
6 cl, 1 dwg, 16 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE AND ITS APPLICATION | 2022 |
|
RU2791523C1 |
METHOD FOR OBTAINING 5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE | 2022 |
|
RU2791916C1 |
5'-O-(4-CHLOROPHENOXYACETYL)-N4-HYDROXYCYTIDINE AND USE THEREOF | 2023 |
|
RU2817609C1 |
5'-O-(4-PHENYLBUTANOYL)-N4-HYDROXYCYTIDINE AND USE THEREOF | 2023 |
|
RU2817201C1 |
USE OF 5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE TO INHIBIT INFLUENZA VIRUS REPLICATION IN VITRO AND IN VIVO | 2022 |
|
RU2791806C1 |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES | 2021 |
|
RU2780252C1 |
URACIL DERIVATIVES WITH ANTIVIRAL ACTIVITY AGAINST SARS-COV-2 | 2021 |
|
RU2769828C1 |
COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
INDOLE-3-CARBOXYLIC ACID DERIVATIVE HAVING ANTIVIRAL ACTIVITY ON SARS-CoV-2 | 2022 |
|
RU2820633C1 |
Authors
Dates
2025-04-17—Published
2024-02-21—Filed